G-CSF Antagonists for Uveitis Treatment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for uveitis, an inflammatory eye condition, often fail to adequately manage inflammation, leading to complications like glaucoma, cataracts, and retinal detachment, and existing therapies may have significant side effects or be ineffective in some patients.

Innovation Solution

The use of antagonists that inhibit granulocyte-colony stimulating factor (G-CSF) or its receptor (G-CSFR) to reduce inflammation in the eyes, either systemically or locally, through antibodies, soluble receptors, or nucleic acid molecules that target G-CSF or G-CSFR expression.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional treatments (steroids, methotrexate, cyclosporine, cyclophosphamide, biologics) are used to treat uveitis, then inflammation is suppressed to some extent, but treatment failure occurs in 5-20% of patients leading to permanent visual loss, or side effects are significant

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts and targets a specific pathway (G-CSF/G-CSFR) that is overactive in uveitis patients, separating the treatment approach from conventional broad-spectrum immunosuppressants. By specifically blocking G-CSF signaling, the therapy addresses the root cause of neutrophil-driven inflammation without the need for multiple systemic immunosuppressive agents, thereby improving treatment reliability while reducing side effects.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent changes the therapeutic parameter from non-specific immunosuppression to specific G-CSF pathway inhibition. This parameter change allows for targeted modulation of neutrophil activity and survival, achieving effective inflammation control with a narrower therapeutic index and fewer adverse effects compared to conventional therapies.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If G-CSF or G-CSFR antagonists are administered to inhibit neutrophil-mediated inflammation, then uveitis symptoms are ameliorated, but neutrophil depletion may occur

Engineering Contradiction:

Improveinflammation controlVSAvoidneutrophil depletion

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent applies partial action by selectively targeting G-CSF signaling in the context of uveitis pathology rather than completely eliminating neutrophil function. The G-CSF antagonist blocks the specific pathway that causes harmful neutrophil accumulation and inflammation, while allowing neutrophils to perform their normal protective functions, thus achieving inflammation control without excessive neutrophil depletion.

Inventive Principle:

Principle #16Partial or excessive action

Solution Approach 2:

The G-CSF antagonist acts as an intermediary that blocks the communication between G-CSF and its receptor, preventing the harmful signaling cascade that leads to neutrophil accumulation and tissue damage. This intermediary blocks the pathological interaction while preserving the physiological role of neutrophils in immune defense.

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS8968731B2Treatment of uveitis

Publication Date: 2015.03.03 CSL LIMITED

AI summary

The present invention relates generally to the use of antagonists of G-CSF, and/or its receptor (G-CSFR) in the treatment of uveitis. The present invention contemplates, therefore, the inhibition of G-CSF or G-CSFR systemically or locally and/or the down-regulation of expression of a G-CSF or G-CSFR in the treatment of uveitis.